Ignite Creation Date:
2025-12-25 @ 4:17 AM
Ignite Modification Date:
2026-01-10 @ 4:10 AM
Study NCT ID:
NCT01544920
Status:
COMPLETED
Last Update Posted:
2018-09-11
First Post:
2012-02-28
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2012-05-30
Start Date Type:
ACTUAL
Primary Completion Date:
2015-05-19
Primary Completion Date Type:
ACTUAL
Completion Date:
2015-05-19
Completion Date Type:
ACTUAL
First Submit Date:
2012-02-28
First Submit QC Date:
None
Study First Post Date:
2012-03-06
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2016-04-22
Results First Submit QC Date:
None
Results First Post Date:
2016-05-30
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-08-13
Last Update Post Date:
2018-09-11
Last Update Post Date Type:
ACTUAL